...Your firm limited the inspection and/or refused to permit the FDA inspection as follows:
1. Barring access to areas
During the inspection, your firm limited the investigator’s access to the manufacturing area. Your employee stated that your firm was currently manufacturing and packaging drug products; however, you prevented the investigator from entering the manufacturing area.
2. Refusal to provide copies of documents
During the inspection, FDA requested records, including a list of drug products you manufacture, as well as some of your facility’s shipping records. Your firm limited the inspection by refusing to provide copies of these records to FDA.
Access to Information During Inspection
When an owner, operator, or agent delays, denies, limits, or refuses an inspection, the drugs may be deemed adulterated under section 501(j) of the FD&C Act....Welp, that's one way to avoid getting a long detailed list of findings.